OTC Markets EXMKT - Delayed Quote USD
Scopus BioPharma Inc. (SCPS)
At close: October 18 at 4:00 PM EDT
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
9,343.0140
11,714.8770
27,634.6190
10,155.8460
2,689.9490
Operating Income
-9,343.0140
-11,714.8770
-27,634.6190
-10,155.8460
-2,689.9490
Net Non Operating Interest Income Expense
--
--
-774.6790
-706.4460
--
Other Income Expense
--
--
1,455.8890
--
--
Pretax Income
-9,343.0140
-11,714.8770
-26,953.4090
-10,862.2920
-2,689.9490
Net Income Common Stockholders
-8,695.8240
-11,609.8270
-26,953.4090
-10,862.2920
-2,689.9490
Diluted NI Available to Com Stockholders
-8,695.8240
-11,609.8270
-26,953.4090
-10,862.2920
-2,689.9490
Basic EPS
-0.31
-0.55
-1.56
-0.81
-0.18
Diluted EPS
-0.31
-0.55
-1.56
-0.81
-0.18
Basic Average Shares
28,088.1040
21,094.2640
17,252.3910
13,362.9590
14,975.6910
Diluted Average Shares
28,088.1040
21,094.2640
17,252.3910
13,362.9590
14,975.6910
Total Operating Income as Reported
--
-11,714.8770
-27,634.6190
-10,155.8460
-2,689.9490
Total Expenses
9,343.0140
11,714.8770
27,634.6190
10,155.8460
2,689.9490
Net Income from Continuing & Discontinued Operation
-8,695.8240
-11,609.8270
-26,953.4090
-10,862.2920
-2,689.9490
Normalized Income
-8,695.8240
-11,609.8270
-28,409.2980
-10,862.2920
-2,689.9490
Interest Expense
--
--
774.6790
706.4460
--
Net Interest Income
--
--
-774.6790
-706.4460
--
EBIT
-9,343.0140
-11,714.8770
-26,178.7300
-10,155.8460
-2,689.9490
EBITDA
-9,341.9120
-11,713.1490
-26,177.2300
-10,154.4060
-2,689.2850
Reconciled Depreciation
1.1020
1.7280
1.5000
1.4400
0.6640
Net Income from Continuing Operation Net Minority Interest
-8,695.8240
-11,609.8270
-26,953.4090
-10,862.2920
-2,689.9490
Total Unusual Items Excluding Goodwill
--
--
1,455.8890
--
--
Total Unusual Items
--
--
1,455.8890
--
--
Normalized EBITDA
-9,341.9120
-11,713.1490
-27,633.1190
-10,154.4060
-2,689.2850
12/31/2019 - 12/16/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ONPH Oncology Pharma Inc.
0.0001
0.00%
VOR Vor Biopharma Inc.
0.6900
-3.75%
RLMD Relmada Therapeutics, Inc.
3.6100
+3.44%
ALGS Aligos Therapeutics, Inc.
7.25
+0.55%
HOWL Werewolf Therapeutics, Inc.
2.0500
0.00%
GNLX Genelux Corporation
2.7500
-2.14%
PSTX Poseida Therapeutics, Inc.
2.4500
-3.54%
SPRB Spruce Biosciences, Inc.
0.5190
+1.76%
COCP Cocrystal Pharma, Inc.
2.0718
+1.56%
RNAC Cartesian Therapeutics, Inc.
22.87
+5.39%